NewAmsterdam Pharma Co N.V. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
NewAmsterdam Pharma terminated Chief Accounting Officer Louise Kooij effective 1 September 2026 (or earlier if she finds other employment) under a settlement agreement. She receives 12 gross monthly salaries as severance (amount not specified in filing), pro-rated 2026 STI bonus at target, continued equity vesting through 10 January 2027, and up to EUR 1,500 legal reimbursement. She retains post-employment confidentiality and non-disparagement obligations. The termination was initiated by the employer with no stated urgent cause.
Why this rating
Executive departure is routine governance matter. Severance at ~12 months salary is standard. No dollar impact disclosed; estimated 1–2% of $1.3B market cap. No operational or strategic disruption evident.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.